Pivotal phase III trial of prostate cancer vaccine [DCVax-Prostate] in patients with non-metastatic hormone-refractory prostate cancer

Trial Profile

Pivotal phase III trial of prostate cancer vaccine [DCVax-Prostate] in patients with non-metastatic hormone-refractory prostate cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2013

At a glance

  • Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 29 Jan 2013 Northwest Biotherapeutics is planning to enter into a partnership in order to progress with this trial programme as announced in a company media release.
    • 25 Apr 2012 Northwest Biotherapeutics is still intending to conduct this trial according to a company media release and the company pipeline.
    • 24 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top